SCHEMBL7138463

SCHEMBL7138463

COC(=O)[C@H](C)NS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.58
HSD17B10 Q99714 2/20 0.58
HTT P42858 1/20 0.58
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 1/20 0.56
HPGD P15428 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.54
MMP2 P08253 4/20 0.54
MMP9 P14780 4/20 0.54
MMP1 P03956 3/20 0.54
MMP13 P45452 3/20 0.54
MMP3 P08254 2/20 0.54
MMP7 P09237 2/20 0.54
CA9 Q16790 3/20 0.53
CA14 Q9ULX7 2/20 0.53
CA12 O43570 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
CA2 P00918 3/20 0.51
SLC1A3 P43003 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25269775 1.00 TSHR (0.58) TSHRHSD17B10HTTALDH1A1KDM4E
SCHEMBL7889040 1.00 TSHR (0.58) TSHRHSD17B10HTTALDH1A1KDM4E
SCHEMBL8446641 0.91 MMP9 (0.64) TSHRHSD17B10HTTALDH1A1KDM4E
SCHEMBL6799581 0.91 TSHR (0.51) TSHRHSD17B10HTTALDH1A1KDM4E
SCHEMBL19404003 0.86 HTT (0.54) TSHRHSD17B10HTTALDH1A1KDM4E
SCHEMBL29541363 0.85 HSD17B10 (0.60) TSHRHSD17B10HTTALDH1A1KDM4E
SCHEMBL6329698 0.85 HSD17B10 (0.60) TSHRHSD17B10HTTALDH1A1KDM4E
SCHEMBL6329696 0.85 HSD17B10 (0.60) TSHRHSD17B10HTTALDH1A1KDM4E
SCHEMBL11578980 0.85 ADAMTS4 (0.59) TSHRHSD17B10HTTALDH1A1HPGD
SCHEMBL1903552 0.85 SLC1A3 (0.56) TSHRHSD17B10HTTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS PROTHENA BIOSCIENCES INC 2025-02-27 US disclosed
CN-118843626-A Heterocyclic compounds as DYRK1A inhibitors 普罗塞纳生物科学有限公司 2024-10-25 CN disclosed
EP-4444421-A2 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS Prothena Biosciences Limited (IE) 2024-10-16 EP disclosed
CN-116332910-A 2-aminopyrimidine derivatives as kinase inhibitors, preparation and use thereof 江苏威凯尔医药科技有限公司 2023-06-27 CN disclosed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed
EP-2246331-A1 NR2B-selective NMDA-receptor antagonists Westfälische Wilhelms-Universität Münster (DE) 2010-11-03 EP disclosed
WO-2010122134-A1 NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS Westfälische Wilhelms Universität Münster (DE) 2010-10-28 WO disclosed
US-6509506-B1 Asymmetric aminohydroxylation of olefins using osmium catalyst; oxidation THE SCRIPPS RESEARCH INSTITUTE 2003-01-21 US disclosed
US-5994583-A Two step synthesis of D- and L- α-amino acids and D- and L- α-amino-aldehydes THE SCRIPPS RESEARCH INSTITUTE (US) 1999-11-30 US disclosed
US-5859281-A Catalytic asymmetric aminohydroxylation of olefins with sulfonamides THE SCRIPPS RESEARCH INSTITUTE (US) 1999-01-12 US disclosed
WO-1997044316-A9 CATALYTIC ASYMMETRIC AMINOHYDROXYLATION OF OLEFINS WITH SULFONAMIDES 1998-04-09 WO disclosed
WO-1997044316-A1 CATALYTIC ASYMMETRIC AMINOHYDROXYLATION OF OLEFINS WITH SULFONAMIDES THE SCRIPPS RESEARCH INSTITUTE (US) 1997-11-27 WO disclosed
WO-1997044312-A1 TWO STEP SYNTHESIS OF D- AND L- α-AMINO ACIDS AND D- AND L- α-AMINO ALDEHYDES THE SCRIPPS RESEARCH INSTITUTE (US) 1997-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS DYRK1A, DYRK2, DYRK1B TSHR 1011/4885HSD17B10 2827/4885HTT 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.